Skip to content Skip to footer
VIEWPOINTS_Micki Hultquist_2024

AstraZeneca at ACR 2023: Micki Hultquist Shares Post-hoc Analysis of Saphnelo

Shots: AstraZeneca at ACR 2023 presented 18 abstracts from its respiratory and immunology pipelines Micki Hultquist in a stimulating conversation with PharmaShots sheds light on Saphnelo, AstraZeneca’s first-in-class biologic treatment for systemic lupus erythematosus (SLE) The post-hoc analysis of the TULIP P-III program reveals that the patients showcased more frequent and sustained remission as compared…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]